Teriflunomide capsule

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Relapsing Multiple ScelrosisRelapsing Multiple Sclerosis

Phase 3

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

CompletedNCT02792231

Novartis PharmaceuticalsRelapsing Multiple Scelrosis

Start: 2016-08-26End: 2020-10-22Updated: 2021-11-22

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

CompletedNCT02792218

Novartis PharmaceuticalsRelapsing Multiple Sclerosis

Start: 2016-09-20End: 2020-07-20Updated: 2021-10-01

Related Papers

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis

Frontiers in Neurology2024-10-244 citations

Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.

2024-07-174 citations

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis (P9-6.007)

Neurology2024-04-09

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension

Multiple Sclerosis Journal2023-09-1136 citations

Compliance and Persistence With Ofatumumab Treatment in Patients With Relapsing Multiple Sclerosis in Clinical Trials for Up to 4 Years (P8-3.002)

Neurology2023-04-255 citations

Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis (P6-3.005)

Neurology2023-04-252 citations

Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013)

Neurology2023-04-251 citations

Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age (P6-3.016)

Neurology2023-04-251 citations

Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.

2022-07-0410 citations

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

Multiple Sclerosis Journal2022-03-1089 citations

Ofatumumab versus Teriflunomide in Multiple Sclerosis

New England Journal of Medicine2020-08-05649 citations